{"id":"exparel-tap-multi-modal-pain-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Postoperative nausea and vomiting"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL3272563","moleculeType":"Protein","molecularWeight":"1153.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Exparel (liposomal bupivacaine) uses DepoFoam technology to encapsulate bupivacaine in lipid vesicles, enabling sustained release of the local anesthetic over 72 hours. When used as part of a transversus abdominis plane (TAP) block combined with multimodal analgesia (typically including NSAIDs, acetaminophen, and/or opioids), it provides regional anesthesia that reduces postoperative pain and opioid consumption.","oneSentence":"Exparel is a liposomal bupivacaine formulation that provides prolonged local anesthesia when infiltrated into surgical sites, often combined with other pain management modalities to reduce opioid requirements.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:36:37.881Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Infiltration anesthesia and nerve block in surgical procedures"},{"name":"Transversus abdominis plane (TAP) block for abdominal surgery pain management"}]},"trialDetails":[{"nctId":"NCT03853694","phase":"PHASE4","title":"Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section","status":"COMPLETED","sponsor":"Pacira Pharmaceuticals, Inc","startDate":"2019-03-04","conditions":"Elective Cesarean Section, Pain Management","enrollment":167}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Exparel TAP + multi-modal pain regimen","genericName":"Exparel TAP + multi-modal pain regimen","companyName":"Pacira Pharmaceuticals, Inc","companyId":"pacira-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Exparel is a liposomal bupivacaine formulation that provides prolonged local anesthesia when infiltrated into surgical sites, often combined with other pain management modalities to reduce opioid requirements. Used for Infiltration anesthesia and nerve block in surgical procedures, Transversus abdominis plane (TAP) block for abdominal surgery pain management.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}